FDA Approves Merck's KEYTRUDA + Padcev Regimens For Muscle-Invasive Bladder Cancer

Merck (MRK) said the FDA approved KEYTRUDA and KEYTRUDA QLEX—its anti–PD-1 therapies—in combination with Padcev (enfortumab vedotin-ejfv). The approval expands the use of its flagship immunotherapy franchise alongside its antibody-drug conjugate, supporting incremental revenue optionality. This is a positive regulatory milestone likely to be supportive for sentiment and near-term trading in MRK.

Analysis

Merck (MRK) said the FDA approved KEYTRUDA and KEYTRUDA QLEX—its anti–PD-1 therapies—in combination with Padcev (enfortumab vedotin-ejfv). The approval expands the use of its flagship immunotherapy franchise alongside its antibody-drug conjugate, supporting incremental revenue optionality. This is a positive regulatory milestone likely to be supportive for sentiment and near-term trading in MRK.